ProTCE-PSMA / Jiangsu Hengrui Pharma - LARVOL DELTA

ProTCE-PSMA, a novel therapeutic PSMA/CD3 prodrug for prostate cancer (AACR 2026) - "JANX007, a phase Ib stage PSMA/CD3 prodrug, achieved the first clinical PoC of conditionally activated TCE, yet its CRS profile and clinical efficacy were still not satisfying. Indeed, in a H2H exploratory toxicity study in cynomolgus monkeys, at 1.5mpk, ProTCE-PSMA induced 10-fold lower cytokine levels than HRP358, and AST and ALT were maintained within the normal range.In conclusion, ProTCE-PSMA is a novel TCE prodrug which demonstrated potent in vivo antitumor activity, satisfying PK profiles and superior therapeutic index. IND filling is expected in Q1, 2026."

Late-breaking abstract • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor • FOLH1